DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET

Company Participants

Rick Pauls - President and Chief Executive Officer

Kirsten Gruis - Chief Medical Officer

Conference Call Participants

Thomas Flaten - Lake Street Capital Markets

Alexander Nowak - Craig-Hallum Capital Group

Francois Brisebois - Oppenheimer & Co. Inc.

Elemer Piros - ROTH Capital Partners

Operator

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2022 Conference Call. An audio recording of the webcast would be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

Before the Company proceeds with its remarks, please note that the Company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note Regarding Forward-Looking Statements in the Company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K. DiaMedica's SEC filings are available at www.sec.gov and on its website.

Please note that any comments made on today's call speak only as of today May 5, 2022, and may no longer be accurate at the time of any replay or transcript rereading. DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, we will open the phone lines for questions.

I would now like to introduce your host for today's call Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin.

Rick Pauls

Thank you, Julie. Good morning, everyone, and welcome to our first quarter 2022 conference call. I'm happy to be able to speak with you this morning. I'm joined by Dr. Kirsten Gruis, our Chief Medical Officer; our CFO, Scott Kellen is sick today and won't be joining us.

I want to start off today addressing the progress in our ReMEDy2 stroke trial in which we are studying DM199 potential to improve the physical recoveries and the rate of stroke recurrence in acute ischemic stroke patients, who have no current treatment options other than supportive care. Remember, this group represents about a half a million patients in the U.S. alone.

Less than two months since our last call, on March 15, we are pleased to share that we have made considerable progress, and I'd like to ask Kirsten to provide a clinical update.